Ultragenyx’s Setrusumab Misses Primary Endpoints i...
Category : Clinical Trial Update 2 January 2026Ultragenyx’s Setrusumab Misses Primary Endpoints in Phase 3 OI Trials, Shows Bone Density Gain...
Newsletter - All News
Newsletter- All News is a comprehensive section of updated news and current trends, specifically curated to keep clinical trials, including breakthroughs in drug research, regulatory approvals, and advancements in study methodologies. Our news covers key trends in trial designs, patient recruitment strategies, and cutting-edge technologies shaping the future of clinical research
ImmunoForge Heads to JPM 2026 to Seek Global Partn...
Category : Clinical Trial Update 2 January 2026ImmunoForge Heads to JPM 2026 to Seek Global Partners for FDA-Cleared Phase 2 Assets Clinical-sta...
Diamyd Medical accelerates primary efficacy readou...
Category : Clinical Trial Update 31 December 2025Diamyd Medical, a company develops precision medicine therapies to prevent and treat type 1 diabetes...
Mabwell Announces First Patient Dosed in Phase II...
Category : Clinical Trial Update 31 December 2025Mabwell (688062.SH), an innovation-driven biopharmaceutical company with a fully integrated industry...
ROSM Selected to Lead Groundbreaking Clinical Tria...
Category : Clinical Trial Update 31 December 2025Regenerative Orthopedics & Sports Medicine (ROSM) is proud to announce its selection as a premie...
Latest Newsletter Post
-
ImmunoForge Heads to JPM 2026 to Se..
2 January 2026
-
Ultragenyx’s Setrusumab Misses Prim..
2 January 2026
-
ROSM Selected to Lead Groundbreakin..
31 December 2025
-
Mabwell Announces First Patient Dos..
31 December 2025
-
Diamyd Medical accelerates primary..
31 December 2025
Subscribe to Our Newsletter!
C-89, Sector-65 Noida-U.P. 201301 (India)
Phone: +91-120-6631301-361
Mobile: +91-9990237670
Customer Care: 18004190155
Email: info@lifescienceintellipedia.com
Email: sales@lifescienceintellipedia.com